Pradana Zaky Romadhon Ami Ashariati Siprianus Ugroseno Yudho Bintoro Satriyo Dwi Suryantoro Choirina Windradi Bagus Aulia Mahdi Krisnina Nurul Widyastuti Etha Dini Widiasi Kartika Prahasanti Aditea Etnawati Putri Narazah Mohammad Yusoff a Department of Internal Medicine,Faculty of Medicine,Universitas Airlangga Hospital,Universitas Airlangga,Surabaya,Indonesiab Institute of Tropical Disease,Tropical Hematologic Rare Disease,Universitas Airlangga,Surabaya,Indonesiac Department of Internal Medicine,Faculty of Medicine,Universitas Airlangga,Surabaya,Indonesiad Faculty of Medicine,Universitas Muhammadiyah Surabaya,Surabaya,Indonesiae Department of Clinical Pathology,Faculty of Medicine,Universitas Airlangga Hospital,Universitas Airlangga,Surabaya,Indonesiaf Advanced Medical and Dental Institute,Universiti Sains Malaysia (USM),Penang,Malaysia

Abstract:Patients suffering from thalassemia are recipients of routine transfusions leading to hemosiderosis. Taking iron chelating agents is mandatory. Several studies have shown different results regarding the occurrence of kidney complications in thalassemia patients who received iron-chelating agents. In this study, we were looking for kidney complications by examining human NAG urine/serum and NGAL urine/serum in thalassemia community in East Java community. The study was conducted cross-sectionally in the thalassemia community in East Java with a total sample of 91 patients aged 13–48 years. All thalassemia patients filled in demographic data, transfusion routines, duration of taking iron chelating agents, and length of time diagnosed with thalassemia. Laboratory tests included routine blood tests for ferritin, ureum, serum creatinine, human NAG urine or serum, and human NGAL urine or serum. Comparison tests ( t -test, Mann-Whitney, and ANOVA, Kruskal-Wallis) were conducted to see if there were significant differences in the levels of human NAG urine and human NGAL urine serum based on age, sex, blood group, duration of transfusion, routine of transfusion, duration of taking iron chelating agents, and types of iron chelating drugs. Multivariate analysis was conducted to see whether some of these categories were related to abnormalities in human NAG urine or serum and human NGAL urine or serum. All 91 patients had normal creatinine values, yet some had abnormal serum NAG. There is a significant difference in urine human NAG and urine human NGAL levels at ages over 23 years ( p = 0.05 and p = 0.01). Significant differences in human NGAL serum were also found in working and student patients ( p = 0.028). Serum NGAL also differed in those taking deferasirox ( p = 0.030) and significantly different human NGAL urine was also found in iron overload status (Ferritin ≥ 1000 ng.ml) ( p = 0.006). There is no difference between human NAG urine/serum and human NGAL urine/serum based on sex, body mass index, blood type, hemoglobin less than 10 g/dl, routine transfusion once a month, duration of using iron chelation for more than 10 years, or splenomegaly status (splenomegaly, splenectomy, or no splenomegaly). The multivariate logistic regression results showed that age above 23 was a factor associated with abnormal urine human NAG levels (aOR = 3.79, 95% CI = 1.08–13.28). Students (aOR = 4.89, 95% CI = 1.48–16.16) with ages above 23 years (aOR = 3.69, 95% CI = 1.09–12.43) showed higher risk for an abnormal serum human NGAL levels. Patients with beta-thalassemia major exhibit noticeable tubular damage. Further research is encouraged to determine other factors behind tubular damage in the thalassemia community, particularly in Indonesia.

Estimated Glomerular Filtration Rate in Pediatric Patients with β-Thalassemia Major: A Single-Center Observational Study at Dr. M. Djamil General Hospital, Padang, Indonesia

Renal Dysfunction in Pediatric Patients in Iraq With β-Thalassemia Major and Intermedia

Novel biochemical markers for the prediction of renal injury in beta-thalassemia major pediatric patients

Prevalence of pulmonary hypertension in pediatric patients with beta-thalassemia major in Central India: a cross sectional study

SERUM CYSTATIN-C VERSUS URINARY ALBUMIN CREATININE RATIO AS AN EARLY INDICATOR OF KIDNEY DYSFUNCTION IN CHILDREN AFFECTED BY B-THALASSEMIA MAJOR

β2-Microglobulin, Neutrophil Gelatinase-Associated Lipocalin, and Endocan Values in Evaluating Renal Functions in Patients with β-Thalassemia Major

Existing Tubular Injury in β-Thalassemia Major Patients Receiving Iron Chelating Agents with Normal Creatinine Level in East Java, Indonesia

Cystatin C-derived estimated glomerular filtration rate in children with sickle cell anaemia

Blood transfusion therapy for β-thalassemia major and hemoglobin E β-thalassemia: Adequacy, trends, and determinants in Sri Lanka

Evaluation of the levels of the markers of ineffective erythropoiesis (transforming growth factor-beta, growth differentiation factor 15 and erythropoietin) in patient with ß-thalassemia syndrome and its correlation to clinical and hematological parameters

High Serum Ferritin Levels among Blood Transfused Thalassemic Patients Admitted to the Department of Paediatrics in a Tertiary Care Centre: A Descriptive Cross-Sectional Study

Study of thyroid function in Egyptian children with β-thalassemia major and β-thalassemia intermedia

Hematological Parameters in Individuals with Beta Thalassemia Trait in South Sumatra, Indonesia

Evaluation of some nonroutine cardiac biomarkers among adults and children with beta-thalassemia major

Netrin-1 and clusterin: Innovative potential diagnostic biomarkers for early renal damage in β-thalassemia major children

Glomerular Filtration Rate Assessment in Children

Novel retinal findings in β-thalassemia major: older age and higher ferritin level as the risk factors

Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with β-Thalassemia Major: A Meta-Analysis

Abnormal glomerular filtration rate in children, adolescents and young adults starts below 75 mL/min/1.73 m2

Markers of Renal Complications in Beta Thalassemia Patients with Iron Overload Receiving Chelation Agent Therapy: A Systematic Review

β-Thalassemia in childhood: Current state of health in a high-income country